Abstract Number: 1096 • 2019 ACR/ARP Annual Meeting
Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Background/Purpose: Electronic health records (EHRs) from large health care systems provide access to rich and comprehensive patient-specific information from many sources consisting of heterogeneous data…Abstract Number: 1493 • 2019 ACR/ARP Annual Meeting
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Background/Purpose: Multiple biologic DMARD (bDMARD) treatments are available for PsA, but there is limited research that compares the safety and efficacy of these treatments. Head-to-head…Abstract Number: 1543 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose of…Abstract Number: 2442 • 2019 ACR/ARP Annual Meeting
The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)
Background/Purpose: Fatigue is a substantial problem in patients with psoriatic arthritis (PsA) that needs to be considered in the core set of domains. This study…Abstract Number: 2460 • 2019 ACR/ARP Annual Meeting
Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is associated with increased disability and mortality, independent of age. Frailty has been evaluated in large datasets…Abstract Number: 2482 • 2019 ACR/ARP Annual Meeting
Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy
Background/Purpose: Growing evidence has pointed gender as a key variable influencing clinical response to biological drugs in psoriatic arthritis(PsA). Although the reasons remain unclear, it…Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…Abstract Number: 836 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
Background/Purpose: Therapeutic options for patients with PsA are increasing but data directly comparing biologics are limited. The multicentre, open-label SPIRIT-H2H trial (NCT03151551) evaluated the efficacy…Abstract Number: 1164 • 2019 ACR/ARP Annual Meeting
Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis
Background/Purpose: Response to treatment in Psoriatic Arthritis (PsA) can be captured using the OMERACT PsA Magnetic Resonance Imaging Score (PsAMRIS). While reliable and valid, PsAMRIS…Abstract Number: 1497 • 2019 ACR/ARP Annual Meeting
Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Background/Purpose: Secukinumab (SEC), a selective inhibitor of interleukin 17A, demonstrated rapid, significant, and sustained improvement in the signs and symptoms of PsA, with a favorable…Abstract Number: 1546 • 2019 ACR/ARP Annual Meeting
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the…Abstract Number: 2443 • 2019 ACR/ARP Annual Meeting
A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis
Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between…Abstract Number: 2463 • 2019 ACR/ARP Annual Meeting
Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV)…Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 81
- Next Page »